Difference between revisions of "Nilotinib (Tasigna)"
Jump to navigation
Jump to search
(Created page with "==General information== Class/mechanism: <ref name="insert">[http://www.pharma.us.novartis.com/product/pi/pdf/tasigna.pdf Nilotinib (Tasigna) package insert]</ref><ref>[http://he...") |
|||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: <ref name="insert">[http://www.pharma.us.novartis.com/product/pi/pdf/tasigna.pdf Nilotinib (Tasigna) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/nilotinib.pdf Nilotinib (Tasigna) package insert (locally hosted backup)]</ref> | + | Class/mechanism: Tyrosine kinase inhibitor of Bcr-Abl, the constitutively active tyrosine kinase resulting from the Philadelphia chromosome abnormality in CML. Nilotinib binds to the inactive conformation of the Abl kinase domain and stabilizes it.<ref name="insert">[http://www.pharma.us.novartis.com/product/pi/pdf/tasigna.pdf Nilotinib (Tasigna) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/nilotinib.pdf Nilotinib (Tasigna) package insert (locally hosted backup)]</ref> |
| − | <br>Route: | + | <br>Route: PO |
| − | <br>Extravasation: | + | <br>Extravasation: n/a |
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>. | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>. | ||
==Patient drug information== | ==Patient drug information== | ||
| + | *[http://www.pharma.us.novartis.com/product/pi/pdf/tasigna.pdf#page=23 Nilotinib (Tasigna) package insert PDF pages 23-27]<ref name="insert"></ref> | ||
*[http://chemocare.com/bio/nilotinib.asp Nilotinib (Tasigna) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/nilotinib.asp Nilotinib (Tasigna) patient drug information (Chemocare)]</ref> | *[http://chemocare.com/bio/nilotinib.asp Nilotinib (Tasigna) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/nilotinib.asp Nilotinib (Tasigna) patient drug information (Chemocare)]</ref> | ||
*[http://www.uptodate.com/contents/nilotinib-patient-drug-information Nilotinib (Tasigna) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/nilotinib-patient-drug-information Nilotinib (Tasigna) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/nilotinib-patient-drug-information Nilotinib (Tasigna) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/nilotinib-patient-drug-information Nilotinib (Tasigna) patient drug information (UpToDate)]</ref> | ||
Revision as of 20:43, 23 February 2012
General information
Class/mechanism: Tyrosine kinase inhibitor of Bcr-Abl, the constitutively active tyrosine kinase resulting from the Philadelphia chromosome abnormality in CML. Nilotinib binds to the inactive conformation of the Abl kinase domain and stabilizes it.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert[1].
Patient drug information
- Nilotinib (Tasigna) package insert PDF pages 23-27[1]
- Nilotinib (Tasigna) patient drug information (Chemocare)[3]
- Nilotinib (Tasigna) patient drug information (UpToDate)[4]